Physician profile

Karl Andersen

Pulmonary Disease · Pittsburgh, PA

NPI 1033564927

$2,492.00

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,190.85
Travel and Lodging$1,078.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Inspire Medical Systems, INC. $1,744.50 2023-2024 Inspire
Boston Scientific Corporation $200.00 2021
Glaukos Corporation $156.12 2023
Glaxosmithkline, LLC. $121.05 2023 Nucala
Zoll Respicardia, INC. $105.00 2024 Remede System
Intuitive Surgical, INC. $100.00 2023 Da Vinci Surgical System
Astrazeneca Pharmaceuticals LP $65.33 2022-2023 Breztri, Tezspire

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Karl Andersen

$2,492.00

in general payments reported 2019-2025

Years
2021-2024
Top company
Inspire Medical Systems, INC.

https://glasscript.com/doctor/5233219/karl-andersen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.